2012 Fiscal Year Final Research Report
Development of enhancement chemotherapy by overcoming an anti-cancer resistant mechanism of AKR1C family
| Project/Area Number |
23659936
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
SHIIBA Masashi 千葉大学, 大学院・医学研究院, 准教授 (20301096)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | アルドースケトース還元酵素 / 口腔癌 / マイクロアレイ解析 / 抗癌剤多剤耐性遺伝子 |
|---|
| Research Abstract |
Using microarray analysis, AKR1C family were up-regulated in all CDDP-resistant cell lines compared with CDDP-sensitive cell lines. We treated the chemoresistant cells with AKR1C siRNA or specific AKR1C inhibitor, mefenamic acid. In vivo, the antitumor growth effect of the combination therapy of mefenamic acid and CDDP/5-FU was greater than that with either mefenamic acid alone or CDDP/5-FU alone. In conclusion, combination CDDP and5-FU chemotherapy with mefenamic acid might be a great therapeutic system for chemoresistant OSCC. Toxicity of combination therapy of CDDP/5-FU and mefenamic acid was evaluated in vitro and in vivo, resulting in the recognition of the safety for the clinical application.
|
